- Home
- Publications
- Publication Search
- Publication Details
Title
Discovery of a PROTAC targeting ALK with in vivo activity
Authors
Keywords
ALK, Degrader, PROTAC, Oral anticancer bioactivities
Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 212, Issue -, Pages 113150
Publisher
Elsevier BV
Online
2021-01-03
DOI
10.1016/j.ejmech.2020.113150
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance
- (2020) Ning Sun et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity
- (2020) Xuan Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
- (2020) Xin Li et al. Journal of Hematology & Oncology
- Development of Selective Histone Deacetylase 6 (HDAC6) Degraders Recruiting Von Hippel–Lindau (VHL) E3 Ubiquitin Ligase
- (2020) Ka Yang et al. ACS Medicinal Chemistry Letters
- PROTAC: A promising technology for cancer treatment
- (2020) Xin Zhou et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Ceritinib ALK T1151R Resistance Mutation in Lung Cancer With Initial Response to Brigatinib
- (2019) Camille Mehlman et al. Journal of Thoracic Oncology
- A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
- (2019) Longchuan Bai et al. CANCER CELL
- A novel ALK inhibitor ZYY inhibits Karpas299 cell growth in vitro and in a mouse xenograft model and induces protective autophagy
- (2019) Jiwei Shen et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein
- (2019) Haibin Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
- (2019) Sajid Khan et al. NATURE MEDICINE
- Development of the first small molecule histone deacetylase 6 (HDAC6) degraders
- (2018) Ka Yang et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)
- (2018) Chengwei Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway
- (2018) Mengchen Lu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)
- (2018) Chelsea E. Powell et al. JOURNAL OF MEDICINAL CHEMISTRY
- Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)
- (2018) Chung Hyo Kang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1
- (2017) Andrew P. Crew et al. JOURNAL OF MEDICINAL CHEMISTRY
- A “Click Chemistry Platform” for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation
- (2017) Ryan P. Wurz et al. JOURNAL OF MEDICINAL CHEMISTRY
- Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals)
- (2017) Matthias Schiedel et al. JOURNAL OF MEDICINAL CHEMISTRY
- Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases
- (2017) Giuseppe Lo Russo et al. Oncotarget
- New strategy for renal fibrosis: Targeting Smad3 proteins for ubiquitination and degradation
- (2016) Xin Wang et al. BIOCHEMICAL PHARMACOLOGY
- Degradation of Akt using protein-catalyzed capture agents
- (2016) Ryan K. Henning et al. JOURNAL OF PEPTIDE SCIENCE
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
- (2016) Kanak Raina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL
- (2015) Ashton C. Lai et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
- (2015) Jing Lu et al. CHEMISTRY & BIOLOGY
- A historical overview of protein kinases and their targeted small molecule inhibitors
- (2015) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
- (2014) L. Friboulet et al. Cancer Discovery
- ALKin Lung Cancer: Past, Present, and Future
- (2013) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
- (2013) Thomas H. Marsilje et al. JOURNAL OF MEDICINAL CHEMISTRY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started